$0.30
▲ +0.7% Today
as of Sep 4, 16:50 ET
Last 30 days
Recent Press Releases & News
IGC Pharma Reports Q2 2026 Results as CALMA Alzheimer's Trial Moves Within Six Randomizations of Enrollment Closure
IGC Pharma Strengthens Regulatory Readiness as Phase 2 CALMA Alzheimer's Trial Approaches Enrollment Closure and Q4 Topline Readout
IGC Pharma Evaluates Potential Recovery Options as Federal Jury Verdict Brings Renewed Attention to 2018 IGC Short Campaign
Overview
52-week range
$0.24
$0.45
28% of range
Avg surprise (last 3)
+27.8%
Avg reaction (last 2)
-1.7%
0% positive
Latest IV / EM
966%
EM ±151.0% · $1 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-0.03 | — | — | — | — | financials |
| Fri May 15, 2026 | Mar/2026 | $-0.02 | $-0.02 | 0.0% | — | -3.3% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.02 | — | — | — | — | financials |
| Thu Aug 14, 2025 | Jun/2025 | $-0.02 | $-0.03 | +33.3% | — | — | earnings |
| Fri Jun 27, 2025 | Mar/2025 | $-0.01 | $-0.02 | +50.0% | — | 0.0% | earnings |
| Mon Mar 31, 2025 | Mar 2025 | $-0.02 | — | — | — | — | financials |
| Tue Dec 31, 2024 | Dec 2024 | $-0.02 | — | — | — | — | financials |
| Mon Sep 30, 2024 | Sep 2024 | $-0.02 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.03 | — | — | — | — | financials |
| Sun Dec 31, 2023 | Dec 2023 | $-0.09 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.05 | — | — | — | — | financials |
| Fri Jul 7, 2023 | Mar/2023 | $-0.08 | — | — | — | — | earnings |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $265,000 | $317,000 | — | $191,000 | $328,000 | $330,000 | $257,000 | $412,000 |
| Cost of revenue | $217,000 | $262,000 | — | $92,000 | $174,000 | $176,000 | $153,000 | $214,000 |
| Gross profit | $48,000 | $55,000 | — | $99,000 | $154,000 | $154,000 | $104,000 | $198,000 |
| Operating income | $-3M | $-2M | — | $-3M | $-2M | $-1M | $-2M | $-2M |
| Net income | $-3M | $-2M | — | $-2M | $-2M | $-1M | $-2M | $-2M |
| EPS (diluted) | $-0.03 | $-0.02 | — | $-0.02 | $-0.02 | $-0.02 | $-0.02 | $-0.02 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $331,000 | $207,000 | $900,000 | $1M | $454,000 | — | $470,000 | $2M |
| Inventory | $640,000 | $638,000 | $640,000 | $658,000 | $1M | — | $1M | $2M |
| Total current assets | $1M | $1M | $2M | $2M | $2M | — | $3M | $4M |
| Total assets | $9M | $9M | $10M | $10M | $8M | — | $9M | $10M |
| Long-term debt | — | — | — | $132,000 | $133,000 | — | $134,000 | $135,000 |
| Total liabilities | $3M | $3M | $2M | $2M | $2M | — | $3M | $3M |
| Total equity | $6M | $6M | $7M | $8M | $6M | $6M | $6M | $7M |